Nonetheless, PARP1 is more abundant in the nucleus, suggesting that the current clinical success of PARPi is heavily reliant on DNA repair inhibition and synthetic lethality, rather than the inhibition of cytoplasmic PARP1-mediated proliferation and survival, in pancreatic cancer [80]. This evidence concerns the gene PARP1 and familial pancreatic carcinoma.